Belimumab is a humanized monoclonal antibody that binds neutralizes BLyS has been effective in SLE treatment.[39] Of note, however, naïve B cells are more susceptible to BLyS inhibition in comparison to memory B cells indicating that BLyS blockade may be more beneficial to target dnDSA in patients rather than highly sensitized patients who have large circulating pools of memory B cells.[22, 28] As seen in the present study, APRIL/BLyS blockade did not consistently decrease memory B cells in sensitized non-transplanted or transplanted groups. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.